Argen X SE ADR

ARGXNASDAQ · USD
960.04USD0.00 (-2.17%)
529

Argen X SE ADR (ARGX) Covered Calls

Argen X SE ADR trades in the Biotechnology industry with an IV Rank of 69.05%, average versus the past year. ARGX's highest covered call setup is the $1,000.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 4.16% out of the money with 7 days to expiration, a 4.43% return until expiration, and a 231.16% theoretical annualized return. Across the setups shown, annualized returns run from 177.89% to 231.16% at strikes between $990.00 and $1,580.00, with 7 to 126 days to expiration, as of Nov 13, 2026.

Read more

Running ARGX covered calls helps you generate income from Argen X SE ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ARGX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ARGX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ARGX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ARGX covered call is worth writing.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

2026-11-2071000.004.162.6010.504256.004.43231.16-0.27+0.23607.90
2026-12-18351160.0020.830.459.1020041.0020.88217.70-0.05+0.09498.65
2027-01-15631300.0035.410.058.8034001.0035.42205.19-0.01+0.0608.75
2026-12-18351140.0018.752.1010.0018206.0018.96197.77-0.22+0.11127.90
2027-01-15631280.0033.330.409.2032036.0033.37193.33-0.04+0.07228.80
2026-11-207990.003.125.2012.803516.003.66190.97-0.54+0.291387.60
2027-03-191261580.0064.580.907.8062086.0064.67187.34-0.09+0.0536.90
2027-01-15631260.0031.241.459.8030141.0031.40181.89-0.15+0.0828.35
2027-02-19981420.0047.910.759.2046071.0047.99178.73-0.08+0.0618.45
2026-12-18351120.0016.663.8012.0016376.0017.06177.89-0.40+0.13178.20

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank69.05% Moderate
  • Market cap (M$)60,377
  • 52 weeks high-10.51%
  • 52 weeks low45.05%
  • Analyst recommendationStrong Buy
    1.22
  • Target price$1,163.83
    21.23% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-10-22
  • P/E36.59
  • Future P/E25.65
  • EPS (ttm)26.24
  • EPS growth next 5 years34.12%

As of Nov 13, 2026